Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Signatera ctDNA after nephrectomy was associated with recurrence in a 77-patient RCC series

A multicenter series of 77 patients with stage I to IV renal cell carcinoma, published in JCO Oncology Advances on January 21, 2026, found that Signatera ctDNA positivity in the molecular-residual-disease window was associated with inferior recurrence-free survival in the landmark analysis (HR 18; 95% CI 4.9 to 67).

JCO Oncology Advances